

## Special Issue

# Editorial Board Members' Collection Series: Utilization of Immune Checkpoint Inhibitors: Past, Present and Future Therapeutics in Cancer

### Message from the Guest Editors

The focus on immune checkpoint involvement in the development of cancer has increased dramatically over the last decade. Dysfunctions in these pathways, leading to excessive activation, inhibits the cells' normal response to damage, leading to unchecked cellular growth. Early pathways, such as the programmed cell death receptor (PD-1) or the cytotoxic lymphocyte-associated molecule-4 (CTLA-4) involved inhibition of the pathway to slow tumor growth. More recent, some checkpoint pathways require stimulation to exert anti-tumor actions. These pathways include CD40 and OX40 pathways. Modifying the tumor microenvironment, thus interfering with cellular energy production and utilization, has become another area of intense interest. The goal of the series is to provide a collection of review and original articles that describe the work that has been done and the outlook for therapeutic developments that target immune checkpoints to attenuate or block cancer development.

### Guest Editors

Prof. Dr. David R. Wallace

Department of Pharmacology & Physiology, School of Biomedical Science, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107-1898, USA

Prof. Giuseppe Murdaca

Department of Internal Medicine, University of Genoa, Genoa, Italy

### Deadline for manuscript submissions

closed (31 March 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/146484](https://mdpi.com/si/146484)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).